



Together, improving life

URGENT MEDICAL DEVICE SAFETY CORRECTION
GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System
DIFFICULTY WITHDRAWING CATHETER

Event Number 2017233.09/09/2020.002-C

September 2020

Dear Health Care Provider:

W.L. Gore & Associates (Gore) would like to inform you of safety information related to the **GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System**. These are devices with catalogue number prefixes **TGM** and **TGMR**. See Appendix 1 for a full list of catalogue numbers.

These updates do **NOT** relate to the Conformable GORE® TAG® Thoracic Endoprosthesis (with the SIM-PULL delivery system), if available in your region. Catalogue numbers beginning with prefix TGU and TGE are not affected.



GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System

Please carefully review this letter and follow all recommended actions described below.

Event Description: Difficulty withdrawing catheter

From August 2019 to January 2020, Gore received five (5) reports where difficulty withdrawing the delivery catheter was encountered due to a proximal stent apex being lodged within the delivery catheter leading olive. Of the five (5) events, four (4) reported health consequences related to increased procedure time and 1 related to surgical intervention. This represents a rate of 0.04% reported complaints of this type of deployment event over the last three (3) years since device commercialization. The investigation of these events determined that a proximal stent apex was unintentionally lodged within the delivery catheter leading olive during the manufacturing process. Gore is implementing manufacturing changes to reduce the possibility of these events. Based on the frequency of these events, Gore estimates that a very small number of the devices in the field globally may be potentially affected by this type of event.

In each event, the physician attempted endovascular techniques to free the stent apex from the leading olive. The techniques included delivery catheter manipulation/movement (e.g. twisting, pushing, and/or pulling) without the use of additional tools; ballooning to force the stent apex apart from the leading olive; and snaring of the catheter or device components. Four (4) of the five (5) events were resolved endovascularly using different combinations of these techniques and the remaining event was resolved with a surgical intervention. In two (2) events that were resolved endovascularly, significant manipulation of the catheter resulted in partial separation of the nitinol stent from the graft material requiring additional stent graft placement to reline and/or secure the separated nitinol stent segment with no additional reports of patient harm.

W. L. Gore & Associates, Inc.
Medical Products Division
P.O. Box 2400
Flagstaff, AZ 86003-2400
USA

Asia Pacific +65 67332882
Europe 00800 6334 4673
United States +1 800 437 8181
United States +1 928 779 2771
goremedical.com



Together, improving life

New IFU Warning: Gore defers to the best medical judgment of physicians to determine the appropriate course of action for the patient if this type of event occurs. As reported, simple endovascular manipulation of the catheter may resolve the issue, but use of balloons, snares and other techniques may be necessary.

Based on these events, Gore will be updating its *Instructions for Use* (IFU) to include a new warning: “Events have occurred where difficulty withdrawing the delivery catheter was encountered due to a proximal stent apex being lodged within the delivery catheter leading olive. Patient harms have been reported including surgical intervention; see ADVERSE EVENTS. If delivery catheter removal difficulty occurs, use best medical judgment to determine the appropriate course of action for the patient. Effective removal of the catheter component has been reported through both surgical and endovascular (catheter manipulation, ballooning, snaring) techniques.”

Reminder of pertinent *Instructions for Use* (IFU) information and warnings:

Deployment events (e.g. removal difficulty) are known complications. For this type of deployment event, although the patient remains hemodynamically stable, attempts to resolve it may lead to potential adverse events per the IFU of surgical conversion; ischemia; stroke; dissection, perforation or rupture of the aortic vessel and surrounding vasculature; harms associated with additional intraoperative and/or secondary surgical or endovascular procedures; and/or harms associated with additional intraoperative procedure time. Attempts at resolution of the event may also lead to catheter breakage; and/or improper placement, material failure, occlusion and fracture of the stent graft.

The IFU currently warns: **Do not continue advancement or retraction of the guidewire, sheath or delivery catheter if resistance is felt. Stop and assess the cause of resistance. Vessel, stent graft or delivery catheter damage may occur.** The IFU similarly warns: **If resistance is felt, stop and assess the cause. Otherwise, device displacement may occur.**

The IFU provides that physicians must have appropriately trained staff, materials and techniques in case there are any events that may require endovascular or surgical intervention. Specifically, Gore recommends that physicians be familiar with ballooning techniques and **have a GORE® Tri-Lobe Balloon Catheter on-hand**, the only recommended balloon to use with this device and specifically designed for use in the thoracic aorta.

Per the IFU, regular and consistent follow-up is a critical part of ensuring the safety and efficacy of aortic endovascular repair. Physicians should tailor patient follow-up to the needs and circumstances of each individual patient.

Gore encourages physicians to adhere to all of the warnings in the IFU. Please refer to the approved IFU for full indications, contraindications, instructions, warnings and precautions, available at: eifu.goremedical.com. This letter will also be available on the Gore Medical website.

Immediate actions for the recipient:

- Take note of amendment/reinforcement of *Instructions For Use* (IFU)
- **Please respond to the enclosed acknowledgment**
- Please share this letter with others in your hospital or clinic as appropriate

Gore is providing physicians with this information so that appropriate risk-related decisions can be made with the patient when considering the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. Gore maintains its confidence in the safety and efficacy of the device and will not be removing GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System from the market.



Together, improving life

There are no actions required for patients already implanted with a GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System.

This safety information serves as a supplement to the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System training in which you participated, and any related educational material you received.

Reference Appendix 1 for additional event information. Please contact Gore Customer Service (email: MPDCustomerCare@wlgore.com or by phone at 800-528-8763) with any questions related to this letter.

Sincerely,

A handwritten signature in black ink that reads "Lena Borbouse".

Lena Borbouse, Ph.D.
Global TAG Conformable Product Specialist

Attachment:
Return acknowledgment form



Together, improving life

APPENDIX 1 – Additional event information

Event number: 2017233.09/09/2020.002-C

Field safety notification type: New

Local representative: John Malone
Global Regulatory Affairs
W. L. Gore & Associates, Inc.
3450 West Kiltie Lane
Flagstaff, AZ 86005
T +1 928 864 3882 M +1 928 864 7251
jmalone@wlgore.com

Device type: System, endovascular graft, aortic aneurysm treatment

Commercial name: GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System

Primary clinical purpose of the device: The GORE® TAG® Conformable Thoracic Stent Graft is indicated for endovascular repair of the descending thoracic aorta.

Device catalogue part numbers:

TGM212110X*	TGM313110X*	TGM404010X*	TGMR313115X*
TGM212115X*	TGM313115X*	TGM404015X*	TGMR313120X*
TGM212120X*	TGM313120X*	TGM404020X*	TGMR312610X*
TGM262610X*	TGM343410X*	TGM454510X*	TGMR373710X*
TGM262615X*	TGM343415X*	TGM454515X*	TGMR373715X*
TGM262620X*	TGM343420X*	TGM454520X*	TGMR373720X*
TGM282810X*	TGM373710X*	TGM262110X*	TGMR404010X*
TGM282815X*	TGM373715X*	TGM312610X*	TGMR404015X*
TGM282820X*	TGM373720X*	TGMR313110X*	TGMR404020X*

*X is a placeholder for enumeration code E = EMEA, Australia, New Zealand, J = Japan

Lot number(s): All lot numbers

Date of first shipment:

EMEA – June 21, 2017

Australia/New Zealand – March 6, 2018

Japan – April 3, 2019

USA – June 14, 2019



Together, improving life

Actions to be taken by the user:

- Take note of amendment/reinforcement of *Instructions For Use* (IFU).
- **Please respond to the enclosed acknowledgment** as soon as possible but no later than **two weeks** after receipt of this notification.
- Please share this letter with others in your hospital or clinic as appropriate.

In the event that an adverse event occurs:

Any adverse event involving the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System should be reported to the manufacturer and the country specific regulatory authorities immediately. To report an event to W. L. Gore & Associates, email: medcomplaints@wlgore.com or contact:

USA: +1.800 528 1866, Ext. 44922, +1 928 864 4922, Fax: +1 928 864 4364

China: +86 21 5172 8237, Fax: +86 21 5172 8236

Japan: +81 3 6746 2562, Fax: +81 3 6746 2563

Brazil: +55 11 5502-7953, Fax: +55 11 5502-7965

EMEA: +49 89 4612 3440, Fax: +49 89 4612 43440

Healthcare professionals and consumers may report adverse events or quality problems directly to FDA using the FDA MedWatch website: <https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>

Depth of communication:

Communication should be disseminated to the user level — Cardiothoracic surgeons, vascular surgeons, interventional cardiologists, interventional radiologists and other physicians implanting endovascular aortic devices.

The regulatory authority of your country has been informed about this communication to customers.

This notice needs to be passed on to all those who need to be aware within your organization or to any organization where potentially affected devices have been transferred (as appropriate). Please transfer this notice to other organization on which this action has an impact (as appropriate).

MD179044 Attachment 1



Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and contraindications for the markets where this product is available. Rx Only

Products listed may not be available in all markets.

GORE, *Together, improving life*, ACTIVE CONTROL, TAG and designs are trademarks of W. L. Gore & Associates.
© 2020 W. L. Gore & Associates, Inc. AZ1768-EN1 SEPTEMBER 2020